ALLO – Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.ALLO
$1.08Name : Allogene Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $236,229,504.00
EPSttm : -1.22
Allogene Therapeutics, Inc.
$1.08
12.20%$0.15Float Short %
17.34
Margin Of Safety %
Put/Call OI Ratio
0.2
EPS Next Q Diff
0.04
EPS Last/This Y
0.31
EPS This/Next Y
Price
1.08
Target Price
7.85
Analyst Recom
1.5
Performance Q
-36.09
Relative Volume
5.44
Beta
0.36
Ticker: ALLO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | ALLO | 1.19 | 0.30 | 0.00 | 6537 |
| 2025-07-07 | ALLO | 1.16 | 0.30 | 0.07 | 6558 |
| 2025-07-08 | ALLO | 1.2 | 0.30 | 0.00 | 6550 |
| 2025-07-09 | ALLO | 1.21 | 0.30 | 0.00 | 6558 |
| 2025-07-10 | ALLO | 1.255 | 0.29 | 0.00 | 6718 |
| 2025-07-11 | ALLO | 1.27 | 0.29 | 0.02 | 6782 |
| 2025-07-14 | ALLO | 1.29 | 0.28 | 0.82 | 6898 |
| 2025-07-15 | ALLO | 1.235 | 0.28 | 0.00 | 6945 |
| 2025-07-16 | ALLO | 1.23 | 0.28 | 0.03 | 6949 |
| 2025-07-17 | ALLO | 1.235 | 0.28 | 0.02 | 7000 |
| 2025-07-18 | ALLO | 1.245 | 0.27 | 0.00 | 7125 |
| 2025-07-21 | ALLO | 1.325 | 0.32 | 0.03 | 5989 |
| 2025-07-22 | ALLO | 1.415 | 0.31 | 0.00 | 6251 |
| 2025-07-23 | ALLO | 1.665 | 0.29 | 0.01 | 6527 |
| 2025-07-24 | ALLO | 1.505 | 0.13 | 0.01 | 12275 |
| 2025-07-25 | ALLO | 1.495 | 0.17 | 0.00 | 10308 |
| 2025-07-28 | ALLO | 1.465 | 0.17 | 0.01 | 10302 |
| 2025-07-29 | ALLO | 1.405 | 0.16 | 0.34 | 10467 |
| 2025-07-30 | ALLO | 1.29 | 0.17 | 0.78 | 10469 |
| 2025-07-31 | ALLO | 1.235 | 0.18 | 2.75 | 10702 |
| 2025-08-01 | ALLO | 1.085 | 0.20 | 6.22 | 10864 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | ALLO | 1.19 | 18.6 | - | -1.00 |
| 2025-07-07 | ALLO | 1.15 | 18.6 | - | -1.00 |
| 2025-07-08 | ALLO | 1.20 | 18.6 | - | -1.00 |
| 2025-07-09 | ALLO | 1.21 | 18.6 | - | -1.00 |
| 2025-07-10 | ALLO | 1.26 | 18.6 | - | -1.00 |
| 2025-07-11 | ALLO | 1.28 | 18.6 | - | -1.00 |
| 2025-07-14 | ALLO | 1.29 | 18.6 | - | -1.00 |
| 2025-07-15 | ALLO | 1.24 | 18.6 | - | -1.00 |
| 2025-07-16 | ALLO | 1.23 | 18.6 | - | -1.00 |
| 2025-07-17 | ALLO | 1.24 | 18.6 | - | -1.00 |
| 2025-07-18 | ALLO | 1.25 | 18.6 | - | -1.00 |
| 2025-07-21 | ALLO | 1.33 | 18.6 | - | -1.00 |
| 2025-07-22 | ALLO | 1.41 | 18.6 | - | -1.00 |
| 2025-07-23 | ALLO | 1.66 | 18.6 | - | -1.00 |
| 2025-07-24 | ALLO | 1.51 | 18.6 | - | -1.00 |
| 2025-07-25 | ALLO | 1.50 | 18.6 | - | -1.01 |
| 2025-07-28 | ALLO | 1.46 | 18.1 | - | -1.01 |
| 2025-07-29 | ALLO | 1.40 | 18.1 | - | -1.01 |
| 2025-07-30 | ALLO | 1.29 | 18.1 | - | -1.01 |
| 2025-07-31 | ALLO | 1.23 | 18.1 | - | -1.01 |
| 2025-08-01 | ALLO | 1.08 | 18.1 | - | -1.01 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | ALLO | -0.33 | 5.83 | 17.42 |
| 2025-07-07 | ALLO | -0.33 | 5.83 | 17.42 |
| 2025-07-08 | ALLO | -0.33 | 5.83 | 17.42 |
| 2025-07-09 | ALLO | -0.33 | 5.83 | 17.42 |
| 2025-07-10 | ALLO | -0.33 | 5.83 | 17.42 |
| 2025-07-11 | ALLO | -0.33 | 5.83 | 17.77 |
| 2025-07-14 | ALLO | -0.33 | 5.83 | 17.77 |
| 2025-07-15 | ALLO | -0.33 | 5.83 | 17.77 |
| 2025-07-16 | ALLO | -0.33 | 5.83 | 17.77 |
| 2025-07-17 | ALLO | -0.33 | 5.83 | 17.77 |
| 2025-07-18 | ALLO | -0.33 | 5.83 | 17.77 |
| 2025-07-21 | ALLO | -0.33 | 5.82 | 17.77 |
| 2025-07-22 | ALLO | -0.33 | 5.82 | 17.77 |
| 2025-07-23 | ALLO | -0.33 | 5.82 | 17.77 |
| 2025-07-24 | ALLO | -0.29 | 5.82 | 17.77 |
| 2025-07-25 | ALLO | -0.29 | 5.82 | 17.34 |
| 2025-07-28 | ALLO | -0.29 | 4.34 | 17.34 |
| 2025-07-29 | ALLO | -0.29 | 4.34 | 17.34 |
| 2025-07-30 | ALLO | -0.29 | 4.34 | 17.34 |
| 2025-07-31 | ALLO | -0.29 | 4.34 | 17.34 |
| 2025-08-01 | ALLO | -0.29 | 4.34 | 17.34 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.28
Avg. EPS Est. Current Quarter
-0.26
Avg. EPS Est. Next Quarter
-0.24
Insider Transactions
-0.29
Institutional Transactions
4.34
Beta
0.36
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
9
Growth Score
22
Sentiment Score
6
Actual DrawDown %
97.6
Max Drawdown 5-Year %
-97.8
Target Price
7.85
P/E
Forward P/E
PEG
P/S
P/B
0.61
P/Free Cash Flow
EPS
-1.23
Average EPS Est. Cur. Y
-1.01
EPS Next Y. (Est.)
-1.01
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
5.44
Return on Equity vs Sector %
-89.2
Return on Equity vs Industry %
-70.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Allogene Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 226
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading